Get started
Author

Yasuhiko Hattori

Observed names: Hattori, Yasuhiko, Y Hattori, Y. Hattori, Yasuhiko HATTORI
Observed institutions: Okayama University, Okayama University Hospital, Tsuyama Chuo Hospital, Sumitomo Besshi Hospital, Okayama City General Medical Center, Okayama City Hospital
ORCID: 0000-0003-3737-3604
Observed ORCID: 0000-0003-3737-3604
OpenAlex ID: A5044679356
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
2020 · Hideyuki Arita, Yuko Matsushita, et al. · Acta Neuropathologica Communications · 68
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma
2020 · Motomasa Furuse, Hiroko Kuwabara, et al. · BMC Cancer · 52
PDF
Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration
2021 · Atsuhito Uneda, Kazuhiko Kurozumi, et al. · Acta Neuropathologica Communications · 45
PDF
Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion
2017 · Y Otani, T Ichikawa, et al. · Oncogene · 38
Annexin A2–STAT3–Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma
2020 · Yuji Matsumoto, Tomotsugu Ichikawa, et al. · Acta Neuropathologica Communications · 37
PDF
Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
2019 · Yusuke Tomita, Kazuhiko Kurozumi, et al. · Molecular Cancer Therapeutics · 36
Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab: A Report of Two Cases
2021 · Satoru YABUNO, Satoshi KAWAUCHI, et al. · NMC Case Report Journal · 29
PDF
δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
2019 · Toshihiko Shimizu, Joji Ishida, et al. · Molecular Cancer Therapeutics · 22
PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma
2017 · Yoshihiro Otani, Joji Ishida, et al. · Scientific Reports · 13
PDF
Combination of Ad-SGE-REIC and bevacizumab modulates glioma progression by suppressing tumor invasion and angiogenesis
2022 · Yasuhiko Hattori, Kazuhiko Kurozumi, et al. · PLoS ONE · 7
PDF
[Stent-Assisted Coil Embolization of a Dissecting Aneurysm of the Posterior Cerebral Artery: A Case Report].
2015 · Jun Haruma, Kenji Sugiu, et al. · PubMed · 1
VGLL-fused intraparenchymal schwannoma with EWSR1::VGLL1 fusion: integrated clinicopathological and molecular characterization
2026 · Ryosuke Ikemachi, Yohei Inoue, et al. · Acta Neuropathologica Communications
A Case of Acute Cerebral Infarction Associated with Basilar Artery Entrapment due to a Traumatic Clival Fracture
2026 · Hiroyuki Takagoshi, Yasuhiko Hattori, et al. · Nosotchu
PDF
A rare case of supratentorial ependymosarcoma harboring ZFTA::RELA fusion
2025 · Yuji Matsumoto, Yasuki Suruga, et al. · Brain Tumor Pathology
PDF
A case of delayed multiple brain lesions following stent-assisted coiling of an unruptured cerebral aneurysm in a patient with neuromyelitis optica spectrum disorder
2025 · Kyoichi Watanabe, Koji Tokunaga, et al. · Nosotchu
PDF
10166- Act-9 Translating Basic Research on Ad-reic for Recurrent Glioblastoma Into an Investigator-initiated Clinical Trial
2024 · Yoshihiro Otani, Kazuhiko Kurozumi, et al. · Neuro-Oncology Advances
Exth-04. Combination of Bevacizumab Enhances the Anti-tumor Efficacy of Ad-sge-reic for Glioma
2024 · Yoshihiro Otani, Yasuhiko Hattori, et al. · Neuro-Oncology
PDF
Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
2023 · Yusuke Tomita, Kazuhiko Kurozumi, et al.
Data from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
2023 · Toshihiko Shimizu, Joji Ishida, et al.
Supplementary Figure 2 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
2023 · Toshihiko Shimizu, Joji Ishida, et al.
Supplementary Figure 1 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
2023 · Toshihiko Shimizu, Joji Ishida, et al.
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
2023 · Yusuke Tomita, Kazuhiko Kurozumi, et al.
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
2023 · Yusuke Tomita, Kazuhiko Kurozumi, et al.
Supplementary Figure 1 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
2023 · Yusuke Tomita, Kazuhiko Kurozumi, et al.
Supplementary Figure 3 from δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
2023 · Toshihiko Shimizu, Joji Ishida, et al.
Works count: 45
Citation count: 348
H-index: 9
I10-index: 9
Year
Topic
Type